Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2000

View Archived Issues

Medarex and Eos Biotechnology establish genomics-based antibody drug alliance

NCI extends two CRADAs with Therion Biologics for cancer vaccines

Kyowa Hakko and Geron extend telomerase partnership

Phase III study of ALX1-11 now under way for treatment of osteoporosis

Novel gene therapy reverses atherosclerotic process in mice

First clinical trial of MBI-853NL begins

Campath BLA accepted for filing

Alexion and Brigham & Women's Hospital to develop novel antiinflammatory antibody

Matrix provides development update at BIO CEO

MGI Pharma updates irofulven progress during 1999

Sankyo discovers new antibacterials produced by Streptomyces

Novel vitamin D compounds for cancer, bone disorders

Production, synthesis and activity of new Xenova compounds for immunoinflammatory conditions

Development of cystic fibrosis therapy advances at SciClone

Marine sponges found to produce potent caspase inhibitors

Guanylate cyclase-activating agents in early development at Aventis

Actelion and Genentech to codevelop tezosentan for the U.S. market

Patient dosing begins in phase I study of first anti-HCV ribozyme therapy

Pharmacyclics' texaphyrins now claimed for use in macrophage-mediated conditions

Ganaxolone produces only modest beneficial effects in cerebral hematoma model

Novartis files for U.S., European approval of new IBS treatment

XTL reports on phase I testing of XTL-001 at investor conference

Acute and subchronic testing in mice indicates limited systemic toxicity for GLG-V-13

Itraconazole increases saquinavir exposure in HIV-infected patients, similar to ritonavir

Key development projects on track at Novartis

PDL to humanize Fujisawa antibody

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 11, 2025.
Deep Apple signs big Novo deal for cardiometabolic small molecules
BioWorld
Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
23andme genetic privacy concerns garner Congressional scrutiny
BioWorld MedTech
The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race
BioWorld
3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...